PD-1/PD-L1 Blockade together with Vaccine Therapy Facilitates Effector T Cell Infiltration into Pancreatic Tumors
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
pancreatic cancer
Modality
Monoclonal Antibody
Mechanism
anti-PD-1/PD-L1 checkpoint blockade combined with vaccine
Target
PDCD1 (PD-1), CD274 (PD-L1)
rNPV Envelope
Low
-$37.9M
costs +25% · peak −25%
Base
-$29.9M
cumulative PoS 0.9%
High
-$21.9M
costs −25% · peak +25%
This is an illustrative envelope for a pancreatic IO combination method, not a novel antibody. Phase 2 and Phase 3 PoS are sharply discounted because pancreatic cancer has been a graveyard for vaccine/checkpoint combinations, including the GVAX/CRS-207 ECLIPSE miss.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.70
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.584 — composite-score rank #32 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#19) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
PD-1/PD-L1 blockade plus GVAX-like vaccine method
The direct JHU biology: checkpoint blockade with vaccine-based immunotherapy to facilitate effector T-cell infiltration into pancreatic tumors. It is a combination method around existing checkpoint drugs, not a new mAb.
Criteria 1 and 2: exact mechanism/indication; no product ownership implied.
GVAX Pancreas plus CRS-207 (Aduro) - ECLIPSE cautionary precedent
Closest pancreatic vaccine lineage. ECLIPSE missed the overall-survival endpoint and showed worse median OS for the vaccine/CRS-207 combination than control arms, making it a key cautionary precedent.
Criteria 2 and 3: same pancreatic vaccine lineage and clinical endpoint setting; stale/cautionary only.
Nivolumab / pembrolizumab checkpoint blockade in pancreatic cancer context
Checkpoint blockade validates the PD-1/PD-L1 pathway generally but has limited single-agent efficacy in unselected pancreatic cancer, explaining why combination methods keep being tried.
Criteria 2 and 4: pathway anchor only; not a same-product comparator.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $12.0M | 24 mo | 30.0% | [0] [1] |
| Phase I | $45.0M | 18 mo | 54.0% | [0] [1] |
| Phase II | $115.0M | 30 mo | 18.0% | [1] [2] [3] |
| Phase III | $260.0M | 42 mo | 36.0% | [2] [3] |
| NDA/BLA Review | $15.0M | 12 mo | 84.0% | [2] |
Multiplier handling: Eligible multipliers (serious_unmet_need) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$150.0M peak · WACC 16.0%
Peak revenue. The academic value path is a partnered combination protocol or vaccine/checkpoint adjunct, not full ownership of a checkpoint antibody. The $150M illustrative peak reflects a narrow royalty/milestone-equivalent product envelope in pancreatic cancer after multiple failed pancreatic vaccine programs.
WACC. Pancreatic IO combination risk is extreme because biology is resistant, endpoints are survival-based, and the closest vaccine lineage failed clinically.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$29.9M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$117.1M
P25
-$31.6M
P50 (median)
-$11.8M
P75
-$7.2M
P95
-$3.8M
Prob ≥ 0
0.2%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is a preclinical checkpoint plus vaccine combination method cmo_findings.asset_class_reality | PD-1/PD-L1 Blockade together with Vaccine Therapy Facilitates Effector T Cell Infiltration into Pancreatic Tumors regulatory | 2014-12-01 | high |
Primary Hopkins pancreatic vaccine/checkpoint biology stage_profile.preclinical.pos | PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors peer_review | 2014-12-01 | high |
ECLIPSE trial record comparators[1] | GVAX Pancreas plus CRS-207 ECLIPSE trial trial_disclosure | 2016-05-01 | high |
ECLIPSE missed primary endpoint stage_profile.phase_2.pos | Aduro pancreatic immunotherapy fails Phase 2 news | 2016-05-17 | high |
Thesis
Why this asset earns its rank
This is not a novel mAb; it is a preclinical pancreatic-cancer combination method using existing PD-1/PD-L1 blockade plus vaccine therapy. That distinction matters because the pinned monoclonal_antibody bucket reflects the checkpoint component, not ownership of a checkpoint drug. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified partnership_candidate rather than vc_fundable.
The closest comparators are cautionary. The Hopkins paper supports the immune-infiltration mechanism, but the GVAX/CRS-207 pancreatic vaccine lineage later failed ECLIPSE, and unselected pancreatic cancer remains one of the hardest IO settings. The engine result is -$37.9M to -$21.9M, with a base rNPV of -$29.9M and cumulative PoS of 0.9%; that result should be read as a low-probability partnered-combination envelope, not as a checkpoint-antibody product case.
Verdict: biologically interesting but commercially fragile. It earns its rank through high clinical relevance and checkpoint-bucket biology, while the CMO reality is a pancreatic vaccine/checkpoint method that needs a partner, a biomarker-enriched trial design, and a reason it will beat a long pancreatic-IO failure history.
Key risks
Asset-specific, not generic biotech risks
- Asset-class mismatch: JHU owns a combination method around existing checkpoint drugs and vaccine therapy, not a proprietary PD-1 or PD-L1 antibody.
- Pancreatic IO graveyard: GVAX/CRS-207 failed the Phase 2b ECLIPSE survival endpoint, directly challenging vaccine-based pancreatic immunotherapy.
- Trial-design risk: pancreatic cancer survival endpoints require larger, longer studies, and weak response-rate signals will not be enough.
- Biomarker risk: without a defined immune-inflamed or vaccine-responsive pancreatic subset, the program risks repeating all-comers IO failures.